Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Long-term improvements in signs of vaginal atrophy seen with ospemifene

Oct. 15, 2009

Dapagliflozin improves glycemic control in type 2 diabetes patients and in preclinical models

Oct. 15, 2009

Metabolex reports results from two phase I clinical trials of MBX-2982

Oct. 14, 2009

The FDA has granted marketing approval to CSL Behring's Berinert in HAE

Oct. 14, 2009

Repeat-dosing toxicology studies of ATL-1103 are completed in mice and primates

Oct. 14, 2009

Recent clinical data show advantages of alogliptin plus pioglitazone combination

Oct. 14, 2009

Liraglutide shows advantages over glimepiride in LEAD-2 type 2 diabetes study

Oct. 14, 2009

Dalcetrapib effective and well tolerated in diabetes and metabolic syndrome patients

Oct. 14, 2009

Data show Afresa efficacy in diabetes with no significant effects on lung function

Oct. 14, 2009

Novel TpoR agonists in early development at Shanghai Hengrui

Oct. 13, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...